{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:13:14Z","timestamp":1784308394137,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.tranon.2020.100977","type":"journal-article","created":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T11:27:58Z","timestamp":1607254078000},"page":"100977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation"],"prefix":"10.1016","volume":"14","author":[{"given":"Brendan P.","family":"Hodkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-0134","authenticated-orcid":false,"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ben-Yehuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-2269","authenticated-orcid":false,"given":"Ann","family":"Forslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhit","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Ceulemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Fourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tranon.2020.100977_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.tranon.2020.100977_bib0002","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2020.100977_bib0003","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.tranon.2020.100977_bib0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.tranon.2020.100977_bib0005","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.tranon.2020.100977_bib0006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.tranon.2020.100977_bib0007","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.tranon.2020.100977_bib0008","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.tranon.2020.100977_bib0009","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2020.100977_bib0010","series-title":"IMBRUVICA\u24c7 (ibrutinib) [prescribing information]","year":"2019"},{"key":"10.1016\/j.tranon.2020.100977_bib0011","series-title":"IMBRUVICA (ibrutinib) [summary of Product Characteristics]","year":"2019"},{"issue":"4","key":"10.1016\/j.tranon.2020.100977_bib0012","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.tranon.2020.100977_bib0013","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.tranon.2020.100977_bib0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0015","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0016","doi-asserted-by":"crossref","first-page":"FSO322","DOI":"10.4155\/fsoa-2018-0049","article-title":"Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"4","author":"Galaznik","year":"2018","journal-title":"Future Sci OA"},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2020.100977_bib0019","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2020.100977_bib0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.tranon.2020.100977_bib0021","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100977_bib0022","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","author":"Armand","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.tranon.2020.100977_bib0023","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2018-99-120355","article-title":"A phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation","volume":"32","author":"Jain","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2020.100977_bib0024","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.tranon.2020.100977_bib0025","first-page":"1146","article-title":"Richter's transformation in chronic lymphocytic leukemia","volume":"26","author":"Jain","year":"2012","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.tranon.2020.100977_bib0026","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.tranon.2020.100977_bib0027","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"52","key":"10.1016\/j.tranon.2020.100977_bib0028","doi-asserted-by":"crossref","first-page":"86433","DOI":"10.18632\/oncotarget.13239","article-title":"Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.tranon.2020.100977_bib0029","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."},{"issue":"15","key":"10.1016\/j.tranon.2020.100977_bib0030","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.tranon.2020.100977_bib0031","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"27","key":"10.1016\/j.tranon.2020.100977_bib0032","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.tranon.2020.100977_bib0033","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.tranon.2020.100977_bib0034","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/annonc\/mdw288","article-title":"Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy","volume":"27","author":"Novotny","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40880-017-0262-z","article-title":"Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study","volume":"36","author":"Hu","year":"2017","journal-title":"Chin. J. Cancer"},{"issue":"19","key":"10.1016\/j.tranon.2020.100977_bib0036","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.tranon.2020.100977_bib0037","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.tranon.2020.100977_bib0038","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.tranon.2020.100977_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166266","article-title":"PD-L1 status in refractory lymphomas","volume":"11","author":"Vranic","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100977_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tranon.2020.100977_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104404","article-title":"Kelch-like proteins: physiological functions and relationships with diseases","volume":"148","author":"Shi","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0042","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/intimm\/dxy033","article-title":"Kelch-like protein 14 promotes B-1a but suppresses B-1b cell development","volume":"30","author":"Li","year":"2018","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.tranon.2020.100977_bib0043","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.tranon.2020.100977_bib0044","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1073\/pnas.1921187117","article-title":"Regulation of B cell receptor-dependent NF-kappaB signaling by the tumor suppressor KLHL14","volume":"117","author":"Choi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.tranon.2020.100977_bib0045","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.7150\/thno.22010","article-title":"Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features","volume":"8","author":"Li","year":"2018","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.tranon.2020.100977_bib0046","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3324\/haematol.2016.146571","article-title":"Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene","volume":"102","author":"van der Krogt","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0047","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/ncb3376","article-title":"PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia","volume":"18","author":"Banh","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"11","key":"10.1016\/j.tranon.2020.100977_bib0048","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.tranon.2020.100977_bib0049","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/cancers4041252","article-title":"Emerging roles of ADAMTSs in angiogenesis and cancer","volume":"4","author":"Kumar","year":"2012","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.tranon.2020.100977_bib0050","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1541-7786.MCR-09-0229","article-title":"Emerging roles of the EBF family of transcription factors in tumor suppression","volume":"7","author":"Liao","year":"2009","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2020.100977_bib0051","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12253-016-0042-0","article-title":"Frameshift mutations of AKAP9 gene in gastric and colorectal cancers with high microsatellite instability","volume":"22","author":"Jo","year":"2016","journal-title":"Pathol. Oncol. Res."},{"issue":"4","key":"10.1016\/j.tranon.2020.100977_bib0052","doi-asserted-by":"crossref","first-page":"934-49 e16","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2020.100977_bib0053","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2018.01.04","article-title":"Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 \u226550","volume":"7","author":"Zarogoulidis","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"issue":"7457","key":"10.1016\/j.tranon.2020.100977_bib0054","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.tranon.2020.100977_bib0055","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0056","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-017-14150-0","article-title":"High-risk follicular lymphomas harbour more somatic mutations including those in the AID-motif","volume":"7","author":"Tsukamoto","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0057","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.4081\/hr.2010.e3","article-title":"High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia","volume":"2","author":"Erdfelder","year":"2010","journal-title":"Hematol Rep."},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0058","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat. Immunol."},{"issue":"15","key":"10.1016\/j.tranon.2020.100977_bib0059","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0060","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Ji","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0061","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.tranon.2020.100977_bib0062","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.4049\/jimmunol.0901248","article-title":"CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node","volume":"183","author":"Takeuchi","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2020.100977_bib0063","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fimmu.2019.00630","article-title":"PD-1 primarily targets TCR signal in the inhibition of functional T cell activation","volume":"10","author":"Mizuno","year":"2019","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.tranon.2020.100977_bib0064","doi-asserted-by":"crossref","first-page":"1148-61 e7","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 Cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4049\/jimmunol.172.1.61","article-title":"Sustained IL-12 signaling is required for Th1 development","volume":"172","author":"Athie-Morales","year":"2004","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.tranon.2020.100977_bib0066","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2017.76.8853","article-title":"Ibrutinib as treatment for patients with relapsed\/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study","volume":"36","author":"Gopal","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2020.100977_bib0067","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.tranon.2020.100977_bib0068","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.jmb.2016.12.021","article-title":"RNA exosome and non-coding RNA-coupled mechanisms in AID-mediated genomic alterations","volume":"429","author":"Laffleur","year":"2017","journal-title":"J. Mol. Biol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320304691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320304691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:48:42Z","timestamp":1761835722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320304691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1936523320304691"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100977","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100977"}}